Literature DB >> 29724508

Porcine reproductive and respiratory syndrome virus expressing E2 of classical swine fever virus protects pigs from a lethal challenge of highly-pathogenic PRRSV and CSFV.

Fei Gao1, Yifeng Jiang1, Guoxin Li2, Yanjun Zhou2, Lingxue Yu2, Liwei Li2, Wu Tong2, Hao Zheng2, Yujiao Zhang2, Hai Yu2, Tongling Shan2, Shen Yang2, Huan Liu2, Kuan Zhao2, Guangzhi Tong3.   

Abstract

Porcine reproductive and respiratory syndrome (PRRS) and classical swine fever (CSF) are economically significant diseases that affect the swine industry worldwide. However, the current vaccination strategy, which uses two single live attenuated vaccines, can result in interference for each other. In addition, the universally used CSFV vaccine C-strain does not allow for differentiation of infected and vaccinated animals. In this study, rPRRSV-E2, PRRS virus (PRRSV) expressing CSF virus (CSFV) E2, was constructed by reverse genetics. The E2 gene of CSFV was inserted between ORF1b and ORF2 in the genome of the PRRS vaccine virus, HuN4-F112. A copy of transcriptional regulatory sequence 6 was inserted at the 3' terminal of the exogenous gene to produce CSFV E2 as a unique subgenomic mRNA transcript. The rPRRSV-E2 was stable for at least 25 serial cell passages. Single-shot intramuscular immunization of rPRRSV-E2 into pigs induced PRRSV-specific and CSFV-specific antibodies and fully protected pigs from lethal challenge with highly-pathogenic PRRSV and CSFV. These results demonstrate that a novel strategy for recombinant PRRSV production is effective, and suggest that rPRRSV-E2 is a promising live, virus-vectored vaccine against PRRS and a marker vaccine against CSF.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CSFV E2; Recombinant PRRSV; Viral-vectored vaccine

Mesh:

Substances:

Year:  2018        PMID: 29724508     DOI: 10.1016/j.vaccine.2018.04.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  A Recombinant Porcine Reproductive and Respiratory Syndrome Virus Stably Expressing a Gaussia Luciferase for Antiviral Drug Screening Assay and Luciferase-Based Neutralization Assay.

Authors:  Yanhua Li; Cicheng Ren; Chenxi Li; Yihong Xiao; Yanyang Zhou
Journal:  Front Microbiol       Date:  2022-05-13       Impact factor: 6.064

Review 2.  Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.

Authors:  Qiang Wei; Yunchao Liu; Gaiping Zhang
Journal:  Viruses       Date:  2021-03-10       Impact factor: 5.048

Review 3.  The Development of Classical Swine Fever Marker Vaccines in Recent Years.

Authors:  Fangfang Li; Bingke Li; Xinni Niu; Wenxian Chen; Yuwan Li; Keke Wu; Xiaowen Li; Hongxing Ding; Mingqiu Zhao; Jinding Chen; Lin Yi
Journal:  Vaccines (Basel)       Date:  2022-04-13

4.  Establishment and Application of a Quantitative PCR Method for E248R Gene of African Swine Fever Virus.

Authors:  Liwei Li; Nannan Du; Jinxia Chen; Kuan Zhang; Wu Tong; Haihong Zheng; Ran Zhao; Guangzhi Tong; Fei Gao
Journal:  Vet Sci       Date:  2022-08-08

5.  Identification of E2 with improved secretion and immunogenicity against CSFV in piglets.

Authors:  Huiling Xu; Yanli Wang; Guangwei Han; Weihuan Fang; Fang He
Journal:  BMC Microbiol       Date:  2020-02-04       Impact factor: 3.605

6.  Generation of a Recombinant Porcine Reproductive and Respiratory Syndrome Virus Stably Expressing Two Marker Genes.

Authors:  Hao Wang; Xin Xie; Wei He; Yuxu Wang; Tongwei Ren; Kang Ouyang; Ying Chen; Weijian Huang; Zuzhang Wei
Journal:  Front Vet Sci       Date:  2020-10-22

7.  Recombinant Bivalent Live Vectored Vaccine Against Classical Swine Fever and HP-PRRS Revealed Adequate Heterogeneous Protection Against NADC30-Like Strain.

Authors:  Liwei Li; Jinxia Chen; Zhengda Cao; Yunlei Cao; Ziqiang Guo; Wu Tong; Yanjun Zhou; Guoxin Li; Yifeng Jiang; Changlong Liu; Lingxue Yu; Sina Qiao; Jiachen Liu; Guangzhi Tong; Fei Gao
Journal:  Front Microbiol       Date:  2022-01-05       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.